N/A N=53 Feasibility of Measuring Vertical Perception in Acute Stroke
Stroke
Primary: Bucket Test to Measure Subjective Visual Vertical (SVV). — 3.2 Degrees
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Evaluation of Phe Fluctuation in PKU Pts Treated With PKU GOLIKE Versus Standard Amino Acid Protein Substitute.
Phenylketonurias
Primary: Blood Phe After 7 Days of Each Treatment — 357.5; 294.0; 346.8; 442.4 µmol/L
N/A N=88 Embryo Culture Under Constant 5% vs Gradient 8%, 5%, 2% Oxygen Concentration
Embryonic Development · Embryo Morphokinetics · Embryo Morphometry
Primary: Proportion of Inseminated Oocytes Developed to the Morphologically Optimal Blastocysts on Day 5 — 27; 38 Oocytes
N/A N=130 Evaluation of Objective Pain Measurement Device
Pain · Analgesia · Labor Pain
Primary: Average Self-report Pain Score — 4.08 score on a scale
Phase 2 N=90 Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Ann Arbor Stage II Grade 1 Follicular Lymphoma · Ann Arbor Stage II Grade 2 Follicular Lymphoma · Ann Arbor Stage III Grade 1 Follicular Lymphoma
Primary: Progression Free Survival — 70.7 months
N/A N=198 Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: Percentage of Participants With Remission and Low Disease Activity (LDA) at Month 6 Assessed Using 28-Joint Disease Activity Score C-Reactive Protein (DAS28-4 CRP)…
Phase 1 N=23 Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Solid Tumor · Osteosarcoma
Primary: Dose Escalation Part: Number of Dose-Limiting Toxicities (DLTs) at Each Dose Level on Cycle 1 — 0; 2 Number of DLTs
N/A N=30 Atrial Natriuretic Peptide in Assessing Fluid Status
Fluid Overload · Fluid Loss · Volume Overload
Primary: Number of Patients With Pro-ANP Twofold Raise by the End of Surgery — 17 Participants
Phase 2 N=177 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
High Grade Glioma · Astrocytoma, Grade III · Glioblastoma
Primary: Phase 1: Maximum Tolerated Dose (MTD) of BMX-001 Administered in Combination With Standard RT and TMZ in Newly Diagnosed HGG Patients — NA mg/Participant
Phase 2 N=14 Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes
Latent Autoimmune Diabetes in Adults
Primary: Injection Site Skin Reactions — 4 events
Phase 2 N=15 Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Metastatic Castration-resistant Prostate Cancer · Prostate Cancer · Prostate Neoplasm
Primary: Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence…
N/A N=53 The Effect of Methylphenidate Treatment on Oxidative Stress Levels in Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change in Total Oxidant Status — 6.29; 5.62 U/ml — p=<0.001
Phase 2 N=53 Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
Breast Neoplasm · Metastasis
Primary: Time to Progression — 4.1 months
N/A N=22 PREMIER: PREvention of Metabolic Illness Through prEcision nutRition
Obesity · Type 2 Diabetes · Metabolic Syndrome
Primary: Glucose at Times 30min, 60min, 120min, 180min — 112.9; 119.8; 94.5; 118.4 mg/dL
Phase 3 N=229 Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
HIV Infections · Streptococcus Pneumoniae
Primary: Positive Immune Responses in the Human Immunodeficiency Virus (HIV)-Infected Pneumococcal Conjugate Vaccine (PCV) and Pneumococcal Polysaccharide Vaccine (PPV) Arms…